The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma

Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 3738867e99d6f9ff0727a159fd97228be3f2ae61
First added on: Feb 13, 2025